Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/PRA.0000000000000502 http://scihub22266oqcxt.onion/10.1097/PRA.0000000000000502 C7678348WhyArePatientsWithCOVID-19atRiskforDrug-DrugInteractions!7678348 !33275385     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33275385 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Psychiatr+Pract 2020 ; 26 (6 ): 485-492 Nephropedia Template TP {{tp|p=33275385 |t=2020. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions? |pdf=|usr=}}{{33275385 }} gab.com Text Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions JO: J Psychiatr Pract http://www.kidney.de/pget.php?&tw=1&pmid=33275385 #FOAvip The goal of this column is to provide information to health care professionals about drug-drug interactions (DDIs) and why DDIs are important to consider in those at serious risk of illness with Coronavirus Disease 2019 (COVID-19). Important considerations discussed in this column include the frequency and complexity of multiple medication use, particularly important for the older patient who often has multiple comorbid illnesses. The column covers the following issues: (1) Why patients at high risk for serious illness from COVID-19 are also at high risk for DDIs. (2) Application of results of pharmacoepidemiological studies to the population at risk for serious COVID-19 illness. (3) Mechanisms underlying DDIs, frequency and potential complexity of DDIs, and how DDIs can present clinically. (4) Methods for preventing or mitigating DDIs. (5) An introduction to the University of Liverpool drug interaction checker as a tool to reduce the risk of adverse DDIs while treating patients for COVID-19. Commentary is also provided on issues related to specific psychiatric and nonpsychiatric medications a patient may be taking. A subsequent column will focus on DDIs between psychiatric medications and emerging COVID-19 treatments, as a detailed discussion of that topic is beyond the scope of this column. Twit Text FOAVip Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions ????J Psychiatr Pract http://www.kidney.de/pget.php?&tw=1&pmid=33275385 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33275385 #FOAvip English Wikipedia <ref>{{Cite pmid|33275385 }}</ref> Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions? #MMPMID33275385 Preskorn SH ; Quadri S J Psychiatr Pract 2020[Nov]; 26 (6 ): 485-492 PMID33275385 show ga The goal of this column is to provide information to health care professionals about drug-drug interactions (DDIs) and why DDIs are important to consider in those at serious risk of illness with Coronavirus Disease 2019 (COVID-19). Important considerations discussed in this column include the frequency and complexity of multiple medication use, particularly important for the older patient who often has multiple comorbid illnesses. The column covers the following issues: (1) Why patients at high risk for serious illness from COVID-19 are also at high risk for DDIs. (2) Application of results of pharmacoepidemiological studies to the population at risk for serious COVID-19 illness. (3) Mechanisms underlying DDIs, frequency and potential complexity of DDIs, and how DDIs can present clinically. (4) Methods for preventing or mitigating DDIs. (5) An introduction to the University of Liverpool drug interaction checker as a tool to reduce the risk of adverse DDIs while treating patients for COVID-19. Commentary is also provided on issues related to specific psychiatric and nonpsychiatric medications a patient may be taking. A subsequent column will focus on DDIs between psychiatric medications and emerging COVID-19 treatments, as a detailed discussion of that topic is beyond the scope of this column. |*COVID-19 Drug Treatment [MESH] |*Drug-Related Side Effects and Adverse Reactions/prevention & control [MESH] |*Polypharmacy [MESH] |Adolescent [MESH] |Adult [MESH] |Aged [MESH] |Aged, 80 and over [MESH] |Comorbidity [MESH] |Drug Interactions [MESH] |Humans [MESH] |Middle Aged [MESH] |Risk [MESH] |Substance Abuse Detection/*statistics & numerical data [MESH]Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions? (epmc).pdf DeepDyve Pubget Overpricing